Home › Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients
 

Keywords :   


Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients

2014-07-24 14:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: study phase patients prevention

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.04'Buying a first home is harder when you're single'
27.04This Week in Agribusiness, April 27, 2024
27.04Scentair Adds Patchouli to UK Home Fragrance Offerings
27.04Weekly Recap: Heubach, BASF, PPG Top This Weeks Stories
27.04Commentary: Committed to End Plastic Waste
26.04Dead whistleblower accused Boeing of safety breaches
26.04Introducing Mens Hybrid Skincare Brand Enhanse
26.04Washington Corner April 2024
More »